In the final overall survival analysis, researchers pitted Lu-177-PSMA-617 (Pluvicto) against an ARPI in the second-line ...

Novartis got a clinical data boost that could support its radiotherapy Pluvicto ’s $2 billion-plus peak sales ambition. Pluvicto helped patients with previously treated PSMA-positive metastatic ...

Prostate cancer has become a significant health concern among men, being the second leading cause of death in the United States. While the survival rate in men remains high, those who have ...

New report finds colorectal cancer rising among U.S. adults under 55 Pluvicto, a drug used to treat advanced prostate cancer, is in short supply, the Food and Drug Administration reported last week.

In the Phase 3 study supporting Pluvicto’s new indication, more than 60% of patients in the ARPI arm went on to receive Novartis’ drug, muddying the survival comparison between the two groups.

Novartis (NVS) said on Monday that its radioligand therapy Pluvicto (INN: lutetium 177Lu) met the main goal of a phase 3 trial in certain patients with prostate cancer. Read more.

Radioligand therapy uses radio-labeled antibodies to deliver targeted radiation directly to prostate cancer cells, minimizing damage to healthy tissue, resulting in fewer and less grueling side ...

Novartis has high hopes for newly launched heart drug Leqvio and cancer therapy Pluvicto. To hear CEO Vas Narasimhan tell it, both products are off to a strong start in their multiyear journeys to ...

Pluvicto, a drug to treat metastatic castration-resistant prostate cancer, also known as mCRPC, is in such short supply that its maker, Novartis, said it cannot allow further supply to new ...

Pluvicto demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival (rPFS) in patients with PSMA–positive metastatic castration ...

Novartis’ highly-touted radionuclide therapy Pluvicto met its primary endpoint in a phase 3 trial as a second-line therapy for PSMA-positive metastatic castration-resistant prostate cancer ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis, where Pluvicto (lutetium (177 Lu) vipivotide tetraxetan), plus standard of care (SoC ...